PLoS Med:前列腺癌遗传风险的评估对初级护理中PSA测试使用的影响

2020-04-02 AlexYang MedSci原创

前列腺癌终生遗传风险评估已经是风险分层的一种方法,从而可以用来鉴定那些前列腺特异性抗原(PSA)检测最有价值的人群。最近,有研究人员测试了在一般的实践中引入前列腺癌终生风险遗传测试对未来PSA检测的影

前列腺癌终生遗传风险评估已经是风险分层的一种方法,从而可以用来鉴定那些前列腺特异性抗原(PSA)检测更有价值的人群。最近,有研究人员测试了在一般的实践中引入前列腺癌终生风险遗传测试对未来PSA检测的影响。

研究人员在一般实践水平上进行了随机化的集群随机对照试验(两个组,每组各73人)。在干预实践中,参与者除了进行标准的PSA测试外,还要进行遗传测试(基于33个风险相关的单核苷酸多态性基因型)。这些测试能够提供他们的前列腺癌终生遗传风险信息,并进行正常风险和高风险区分。主要结果为2年内重复进行PSA测试的男性比例,并使用多水平逻辑回归模型测试相关性。研究发现,使用排除标准后,共有3558名男性参与了干预实践,1235(34.7%)名接受了遗传测试,4242名为对照。研究发现,高遗传风险的男性比正常遗传风险的男性具有更高的重复PSA测试倾向(OR=8.94,p<0.01)。上述研究在常规实践中进行并且具有一些选择偏差,即更大比例的年轻人和高收入参与者参与了遗传测试。

最后,研究人员指出,为全科医生(GPs)提供基因检测权限来评估终生前列腺癌的风险并没有减少未来PSA检测的总数量。然而,进行过遗传测试的男性中,遗传风险的认知能够显著的影响未来PSA检测。

原始出处:

Jacob Fredsoe , Jan Koetsenruyter , Peter Vedsted et al. The Effect of Assessing Genetic Risk of Prostate Cancer on the Use of PSA Tests in Primary Care: A Cluster Randomized Controlled Trial. PLoS Med. 07 Feb 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077848, encodeId=764920e78481d, content=<a href='/topic/show?id=e75532239d4' target=_blank style='color:#2F92EE;'>#初级护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32239, encryptionId=e75532239d4, topicName=初级护理)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Sep 10 10:38:17 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271082, encodeId=80a312e1082ea, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361947, encodeId=bf33136194eff, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610401, encodeId=0da1161040193, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040703, encodeId=1a601040e03e1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 02 14:38:17 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077848, encodeId=764920e78481d, content=<a href='/topic/show?id=e75532239d4' target=_blank style='color:#2F92EE;'>#初级护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32239, encryptionId=e75532239d4, topicName=初级护理)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Sep 10 10:38:17 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271082, encodeId=80a312e1082ea, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361947, encodeId=bf33136194eff, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610401, encodeId=0da1161040193, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040703, encodeId=1a601040e03e1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 02 14:38:17 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077848, encodeId=764920e78481d, content=<a href='/topic/show?id=e75532239d4' target=_blank style='color:#2F92EE;'>#初级护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32239, encryptionId=e75532239d4, topicName=初级护理)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Sep 10 10:38:17 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271082, encodeId=80a312e1082ea, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361947, encodeId=bf33136194eff, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610401, encodeId=0da1161040193, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040703, encodeId=1a601040e03e1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 02 14:38:17 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077848, encodeId=764920e78481d, content=<a href='/topic/show?id=e75532239d4' target=_blank style='color:#2F92EE;'>#初级护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32239, encryptionId=e75532239d4, topicName=初级护理)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Sep 10 10:38:17 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271082, encodeId=80a312e1082ea, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361947, encodeId=bf33136194eff, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610401, encodeId=0da1161040193, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040703, encodeId=1a601040e03e1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 02 14:38:17 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
    2020-04-04 智慧医人
  5. [GetPortalCommentsPageByObjectIdResponse(id=2077848, encodeId=764920e78481d, content=<a href='/topic/show?id=e75532239d4' target=_blank style='color:#2F92EE;'>#初级护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32239, encryptionId=e75532239d4, topicName=初级护理)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Sep 10 10:38:17 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271082, encodeId=80a312e1082ea, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361947, encodeId=bf33136194eff, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610401, encodeId=0da1161040193, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Apr 04 02:38:17 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040703, encodeId=1a601040e03e1, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 02 14:38:17 CST 2020, time=2020-04-02, status=1, ipAttribution=)]
    2020-04-02 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Semin Arthritis Rheu:室外空气污染与患类风湿性关节炎风险的关联

现有证据表明,空气污染的某些指标(臭氧、靠近公路和PM2.5)与RA之间存在显著关联。

Heart:强化动机式访谈干预对心血管高风险人群无明显效果

肥胖的流行正导致心血管疾病高危人群的患病率不断上升,进而否定了降低心血管疾病死亡率的医学进展。本研究目的旨在评估评估减轻心血管病高危患者的体重和增加体力活动强化生活方式干预的临床效果和成本效益。

Semin Arthritis Rheu:孕次、产次与患类风湿性关节炎风险之间的关联

这项系统评价不支持孕次和产次与患RA风险之间存在关联的说法。

Ann Rheum Dis:接受手术类风湿性关节炎患者的免疫抑制治疗以及再入院和死亡风险

与甲氨蝶呤相比,近期使用生物制剂或tsDMARD与髋部骨折、腹盆腔或心脏手术后的死亡或再入院风险升高无关。较高剂量的糖皮质激素与风险更高相关。

Heart:盆浴与冠心病和卒中风险的关系

中年人盆浴频率与心血管疾病风险呈负相关

Sci Rep:VI型胶原蛋白α5基因变异可预测中国汉族人群罹患肺癌的风险

COL6A5多态性rs13062453、rs1497305和rs77123808与中国汉族人群的肺癌风险相关。